GSK is shifting to specialty growth (HIV, oncology, asthma) with key launches and a deep late-stage pipeline—still ...

Contract development and manufacturing organization (CDMO) Samsung Biologics made a splash at the end of 2025, acquiring ...

It’s been an upbeat week for GSK as it reported a trio of positive updates stemming from vaccines and oncology products. Most notable, perhaps, was the news that the British drugmaker took a step ...

GSK plc (NYSE:GSK) is one of the best affordable healthcare stocks to buy now. GSK plc (NYSE:GSK) announced on December 19 an agreement with the United States administration to lower the cost of ...

GSK trades at lower price multiples compared to competitors due to weaker pipeline. GSK's revenue growth in 2023 was modest, but it has strong performers in its product mix. GSK needs to demonstrate ...

LONDON/MUMBAI (Reuters) - Indian generics firm Lupin , some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs being ...

GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...

The companies struck a multi-year strategic collaboration, under which GSK will have access to Helix's GenoSphere cohorts.

GSK (GSK) announced that China’s National Medical Products Administration, NMPA, has approved Nucala as add-on maintenance treatment of adult ...

GSK has received approval from China’s National Medical Products Administration for Nucala as an add-on maintenance therapy for adults with inadequately controlled COPD and elevated blood eosinophils.

LONDON/MUMBAI, July 22 (Reuters) - Indian generics firm Lupin, some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs ...